Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology Results

CoSara to Exhibit at MICROCON 2026, the Annual Congress of the Indian Association of Medical Microbiologists

Co-Dx to Host HPV Screening Webinar on November 17 to Support Awareness Across South Asian Markets

SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the publication of a peer-reviewed study using the SARAGENE® Human Papillomavirus High Risk (HPV-HR) Test manufactured by CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India. The study, conducted by investigators at a local institution in Gujarat, India and published in Infectious Agents and Cancer, highlights the potential role of molecular HPV testing in identifying women who warrant further evaluation, even when cytology results are negative.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.